wire - news in brief
Category
Results 51 - 100 of 353.
How do mRNAs deal with stress?
Two hallmarks of the integrated stress response of cells are the inhibition of translation and the formation of stress granules (SGs) and processing bodies (PBs). However, it is not well understood how both processes are coupled. In a study published in Molecular Cell, researchers from the Chao group applied single-molecule RNA imaging to study the interactions of mRNAs with SGs and PBs, and found out that the generally accepted assumptions about the function of granules need to be revised.
Two hallmarks of the integrated stress response of cells are the inhibition of translation and the formation of stress granules (SGs) and processing bodies (PBs). However, it is not well understood how both processes are coupled. In a study published in Molecular Cell, researchers from the Chao group applied single-molecule RNA imaging to study the interactions of mRNAs with SGs and PBs, and found out that the generally accepted assumptions about the function of granules need to be revised.
A walk-through exhibition introduces people to innovative projects from various institutes.
An EPFL researcher has developed a system based on fuel cells to reduce the carbon footprint and energy consumption of cruise ships, which are increasingly popular among vacation goers around the world.
The Botanical Garden of the University of Zurich is displaying large-format pictures of macroalgae taken by photographer Josh Westrich, bringing these maritime organisms into the tropical setting of UZH's greenhouses.
FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq (atezolizumab) in combination with Abra
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq (atezolizumab) in combination with Abra
The study by 153 researchers from 40 countries found that climate factors such as temperature and humidity strongly influence the carbon cycles of river ecosystems.
Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.
EPFL goes to New Zealand to study melting glaciers
Four EPFL researchers will explore New Zealand's glacier-fed streams for two months, marking the first step in a global journey that will take them across 15 countries by 2021.
Four EPFL researchers will explore New Zealand's glacier-fed streams for two months, marking the first step in a global journey that will take them across 15 countries by 2021.
This week, four EPFL-designed drones are being shown in the Swiss Pavilion at the Consumer Electronics Show in Las Vegas.
The weight of elephants living in zoos fluctuates over the course of their adult lives in cycles lasting around a hundred months, researchers at the University of Zurich have found. The fluctuation is linked to the particular pattern of tooth change in elephants, which results in them having more or less chewing surface available.
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are triggered
Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are triggered
Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder
ReSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader f
ReSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader f
This week, eleven EPFL startups are in Las Vegas to tout their technologies at the Consumer Electronics Show, one of the largest events of its kind.
Pushing the boundaries of the visible
Our cutting-edge technology platforms are key enablers of research at the FMI. One of the biggest of these, with the largest number of users, is the Facility for Advanced Imaging and Microscopy (FAIM). To find out more about the facility, and microscopy in general, we spoke to the joint heads of FAIM - Christel Genoud, who is responsible for Electron Microscopy, and Laurent Gelman, responsible for Light Microscopy.
Our cutting-edge technology platforms are key enablers of research at the FMI. One of the biggest of these, with the largest number of users, is the Facility for Advanced Imaging and Microscopy (FAIM). To find out more about the facility, and microscopy in general, we spoke to the joint heads of FAIM - Christel Genoud, who is responsible for Electron Microscopy, and Laurent Gelman, responsible for Light Microscopy.
Novartis receives European Commission (EC) approval for expanded indication for Kisqali (ribociclib)
Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali (ribociclib), the CDK4/6 inhibitor with the largest body of first-li
Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali (ribociclib), the CDK4/6 inhibitor with the largest body of first-li
Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies
Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah (tisagenlecleucel) and recent successful completion of tec
Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah (tisagenlecleucel) and recent successful completion of tec
The National Research Programme "Sustainable Use of Soil Resources" (NRP 68) proposes various measures to safeguard soil quality in Switzerland in the long term. The Centre for Development and Environment (CDE) and the Institute of Geography have investigated the impacts of soil use by Switzerland abroad.
PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA)
PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment
PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment
